Table 4.

Clinical trials of Disitamab vedotin (DV)

Clinical trials	Participants (cTNM/N)	Primary endpoints	Nation
DVa+PD-1 A	cT2-T4aN0-3M0/9	88.9% ORR [59]	China
DVa+PD-1 A	cT2-4bN0-3M0-1a/51	Following [60]	China
DVa+PD-1 A	cT2-4aN0-2M0/11	81.8% ORR [61]	China
DVa+PD-1 A	la/mUC/185	62.5% ORR [55]	China
DVa	la/mUC/43	51.2% ORR [13]	China
DVa	la/mUC/107	50.5% ORR [12]	China
DVa vs DVa+PD-1 A	la/mUC/38	63.2% ORR [62]	China
DV vs DV+PD-1 A	la/mUC/36	38.9% ORR [57]	China

PD-1 A: programmed death-1 antibody (toripalimab or tislelizumabo or pembrolizumab or envafolimab or sintilimab); la/mUC locally advanced or metastatic urothelial carcinoma

^a2 mg/kg, once every 2 weeks